<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03366571</url>
  </required_header>
  <id_info>
    <org_study_id>D161100002716003</org_study_id>
    <nct_id>NCT03366571</nct_id>
  </id_info>
  <brief_title>Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy</brief_title>
  <official_title>Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have completed 3 years follow-up of the past Beijing Science and Technology&#xD;
      Commission Research will receive another 7-years anti-viral therapy. Patients will be&#xD;
      assessed at baseline and every six months for blood cell count, liver function test, HBVDNA,&#xD;
      AFP, prothrombin time, liver ultrasonography, and Fibroscan. CT or MRI and endoscopy will be&#xD;
      performed at baseline and 7 years. At the end of the study, the cumulative rate of clinical&#xD;
      hepatic hard endpoint will be calculated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have completed 3 years follow-up of the past Beijing Science and Technology&#xD;
      Commission Research will receive another 7-years anti-viral therapy. Patients will be&#xD;
      assessed at baseline and every six months for blood cell count, liver function test, HBVDNA,&#xD;
      AFP, prothrombin time, liver ultrasonography, and Fibroscan. CT or MRI and endoscopy will be&#xD;
      performed at baseline and 7 years. At the end of the study, the cumulative rate of clinical&#xD;
      hepatic hard endpoint will be calculated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative rate of liver decompensation and/or hepatic carcinoma and/or liver related death</measure>
    <time_frame>10 years</time_frame>
    <description>Cumulative rate of liver decompensation (including ascites,hepatic encephalopathy,Gastrointestinal hemorrhage)，and/or hepatocellular carcinoma， and/or liver related death after 10 years of antiviral treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV-DNA undetectable rate</measure>
    <time_frame>10 years</time_frame>
    <description>HBV-DNA undetectable rate after 10 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of transient elastography</measure>
    <time_frame>10 years</time_frame>
    <description>Decrease of transient elastography after 10 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion rate</measure>
    <time_frame>10 years</time_frame>
    <description>HBeAg seroconversion rate after 10 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg seroconversion rate</measure>
    <time_frame>10 years</time_frame>
    <description>HBsAg seroconversion rate after 10 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of Child-Pugh score</measure>
    <time_frame>10 years</time_frame>
    <description>Decrease of Child-Pugh score after 10 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of MELD score</measure>
    <time_frame>10 years</time_frame>
    <description>Decrease of MELD score after 10 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of life Quality assessed by SF-36</measure>
    <time_frame>10 years</time_frame>
    <description>Improvement of life Quality assessed by SF-36 after 10 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of life Quality assessed by EQ-5D</measure>
    <time_frame>10 years</time_frame>
    <description>Improvement of life Quality assessed by EQ-5D after 10 years of antiviral treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Anti-viral therapy group</arm_group_label>
    <description>Subjects who have completed the 3 years research &quot;Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non anti-viral therapy group</arm_group_label>
    <description>History study from literature</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleos(t)ide Analogues</intervention_name>
    <description>Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.</description>
    <arm_group_label>Anti-viral therapy group</arm_group_label>
    <other_name>Baraclude , et al</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma and DNA.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The HBV-related chronic hepatitis /cirrhosis patients who have completed 3 years follow-up&#xD;
        of the past Beijing Science and Technology Commission Research.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have participated in the research funded by Beijing science and&#xD;
             Technology Commission and have completed 156 weeks follow-up.&#xD;
&#xD;
          -  Patients comply with the requirements of the trail voluntarily&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman or patient with severe disease&#xD;
&#xD;
          -  Patients with poor adherence to the study&#xD;
&#xD;
          -  Patients not suitable for the study evaluated by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong J Jia, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hopsital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Jidong Jia</investigator_full_name>
    <investigator_title>Director of Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>Liver Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

